Cathepsin S Drives Antigen Processing in Non-Hodgkin Lymphoma

Study Background and Research Question

The tumor microenvironment in non-Hodgkin lymphoma (NHL) is shaped by intricate interactions between malignant B cells and immune cells. Genomic alterations in cancer frequently enable tumor cells to evade immune recognition, impacting disease progression and therapy resistance. In follicular lymphoma, one of the most common NHL subtypes, the cross-talk between B cells and CD4+ T follicular helper (Tfh) cells in germinal centers is critical for malignant expansion. However, the molecular mechanisms governing antigen processing and immune evasion in these lymphomas remain incompletely understood.

Dheilly et al. (2020) set out to elucidate the role of cathepsin S (CTSS), a lysosomal cysteine protease, in the regulation of antigen processing, T cell activity, and lymphoma progression. Their central research question: How does CTSS activity influence antigen presentation and the anti-tumor immune response in follicular lymphoma?

Key Innovation from the Reference Study

The major innovation in this study lies in identifying a recurrent activating mutation (Y132D) in cathepsin S among follicular lymphoma patients and demonstrating that CTSS is both overexpressed and mutated in this disease. By dissecting the consequence of CTSS modulation, Dheilly et al. provide direct mechanistic evidence that CTSS regulates the repertoire of antigens presented by malignant B cells, thus controlling communication with CD4+ Tfh cells and recognition by cytotoxic CD8+ T cells. Importantly, they show that inhibition or loss of CTSS activity can convert the immunologically “cold” tumor microenvironment to a more “hot” state, enhancing CD8+ T cell infiltration and anti-tumor immunity.

Methods and Experimental Design Insights

The study employed an integrative approach combining patient sample analysis, genetically engineered mouse models, and in vitro mechanistic assays. Key methodological highlights include:

• Genomic profiling of follicular lymphoma patient cohorts to identify recurrent CTSS mutations and expression changes.
• Generation of CTSS knockout (KO) and Y132D knock-in mouse lymphoma models to dissect the causal role of cathepsin S in vivo.
• Flow cytometry and immunohistochemistry to quantify T cell infiltration and phenotype in lymphoma tissues.
• Mass spectrometry and peptide elution assays to characterize the diversity of antigens presented on MHC class I and II molecules.
• Co-culture experiments to assess the effects of altered antigen processing on Tfh cell help and CD8+ T cell activation.

This multifaceted strategy allowed the authors to connect genetic alterations with functional immune consequences and tumor outcomes.

Core Findings and Why They Matter

Several key discoveries emerged from this work:

• CTSS is recurrently mutated and overexpressed in follicular lymphoma. The Y132D mutation enhances CTSS enzymatic activity, as shown by biochemical assays and structural modeling (Dheilly et al., 2020).
• Cathepsin S regulates antigen processing and presentation. Loss of CTSS activity leads to diversification of peptides loaded onto MHC class I and II molecules, shifting the antigenic landscape of tumor cells.
• Immune cell cross-talk is CTSS-dependent. High CTSS activity maintains effective communication between malignant B cells and CD4+ Tfh cells, which supports lymphoma growth. In contrast, CTSS inhibition disrupts this axis and promotes CD8+ T cell infiltration.
• Therapeutic potential of CTSS inhibition. In mouse models, genetic or pharmacologic suppression of CTSS slowed lymphoma progression and increased tumor immunogenicity, suggesting a novel avenue for immunomodulatory therapy in NHL.

This evidence positions cathepsin S as a non-redundant regulator of tumor-immune interactions and highlights cysteine protease inhibition as a rational strategy to enhance anti-tumor immunity in lymphoid malignancies.

Comparison with Existing Internal Articles

The findings of Dheilly et al. align with and extend prior research on cysteine protease inhibition and its impact on antigen processing. Internal articles such as "E-64 in Antigen Processing: Unveiling New Cancer Immunology Tools" discuss how L-trans-epoxysuccinyl peptide inhibitors, including E-64, can modulate antigen processing and tumor immunogenicity. This complements the reference study’s demonstration that targeting cysteine proteases (specifically CTSS) can diversify antigen presentation and support anti-tumor T cell responses.

Other internal reviews, like "E-64 L-trans-Epoxysuccinyl Peptide: Precision Cysteine Protease Inhibition", emphasize the selectivity and translational utility of E-64 for mechanistic studies in cancer and immunology. The reference study’s use of both genetic and pharmacological CTSS inhibition provides a direct mechanistic link to these applications, illustrating how established tools like E-64 can support research into antigen processing and immune modulation.

On the other hand, data from studies such as "Chronic E-64 Cathepsin Inhibition in Salt-Sensitive Hypertension" caution that the effects of cysteine protease inhibition may be context-dependent, as E-64 did not alter outcomes in a non-cancer model. This underscores the importance of mechanistic context when applying inhibitors to new disease settings.

Limitations and Transferability

While the study by Dheilly et al. provides compelling evidence for the role of CTSS in antigen processing and immune regulation in lymphoma, several limitations should be noted:

• Model specificity: The major findings were established in follicular lymphoma and genetically engineered mouse models. The relevance to other lymphoma subtypes or solid tumors requires further validation.
• Complexity of immune networks: Modulating a single protease may have variable effects depending on the broader tumor microenvironment and the presence of compensatory mechanisms.
• Pharmacologic vs. genetic inhibition: While genetic KO models provide clear mechanistic insights, translational application depends on the specificity, bioavailability, and safety of pharmacological inhibitors in vivo.

Despite these caveats, the demonstration that CTSS inhibition can diversify tumor antigens and potentiate CD8+ T cell responses supports its potential as a target for immunomodulatory therapies in lymphoma.

Protocol Parameters

• Cathepsin S inhibition: Genetic knockout or pharmacological inhibition (e.g., using irreversible L-trans-epoxysuccinyl peptide inhibitors such as E-64) can be applied in vitro or in vivo to study antigen processing.
• Antigen presentation assays: Use mass spectrometry or peptide elution to assess changes in MHC-associated peptide repertoires following protease inhibition.
• T cell infiltration quantification: Deploy flow cytometry or immunohistochemistry to measure CD4+ and CD8+ T cell subsets in tumor tissue after intervention.
• Recommended inhibitor concentrations: For E-64, literature suggests low nanomolar to micromolar concentrations, with product reports indicating IC₅₀ values in the 1–100 nM range depending on the target protease and assay format (APExBIO product data).
• Solubilization: For optimal results, dissolve E-64 at ≥49 mg/mL in water or ≥53 mg/mL in DMSO, warming at 37°C or using ultrasonication as needed (product details).

Research Support Resources

Researchers seeking to investigate cysteine protease inhibition, antigen processing, or immunomodulation in lymphoma and related models can utilize well-characterized inhibitors such as E-64 (SKU A2576) from APExBIO. E-64’s irreversible, covalent binding to cysteine proteases—including cathepsin S—makes it a robust tool for both mechanistic studies and quantitative enzyme assays. For protocol details and recommended usage, refer to the product specifications and literature above. While E-64 is not a therapeutic agent, its application in research workflows is directly supported by the mechanistic findings of Dheilly et al. (2020) and related studies.